MRK241227C135000
- 0.00
- 0.000.00%
Merck & Co Newsroom
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?
CICC: Maintains HANSOH PHARMA "Outperform Industry" rating with a Target Price of HKD 21.12.
CICC released a research report stating that it maintains a "outperform the Industry" rating for HANSOH PHARMA (03692), being Bullish on the company's future progress in going global, and maintains a Target Price of HKD 21.12. Due to the possibility that the initial payment for this authorized cooperation may be confirmed in 2025, the bank has lowered its expectations for 2024 authorized revenue and maintained its expectations for 2025 authorized fees, thus reducing the 2024 profit forecast by 9.7% to 4.04 billion yuan while keeping the 2025 profit forecast unchanged. On December 18, 2024, the company announced the granting of a global exclusive license agreement for Merck's HS-10535 (oral GLP-1 receptor agonist). CICC
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025 -- Barrons.com
Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website
Dow Rallies 117 Points On Gains For NVIDIA Corp., UnitedHealth Stocks
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck Downgraded by BMO Over Keytruda Concerns
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Investing in Merck (NYSE:MRK) Three Years Ago Would Have Delivered You a 43% Gain
Merck & Co., Inc. (MRK) Is Attracting Investor Attention: Here Is What You Should Know
Express News | Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024...
Merck: Will Record Pretax Chg Relating to Upfront Payment of $588M, or 18c/Shr, in 4Q Results >MRK
Express News | Merck & Co Inc - to Record $588 Million Pre-Tax Charge in Q4 2024 Related to Agreement